Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab with Cetuximab and Irinotecan in Metastatic Colorectal Cancer
NCT00551421Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2007
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase II Dose at 28 days and Objective Tumor Response Rate. Started Oct 2007; status: completed.
02
Drugs
pertuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00551421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551421.